The heart’s constant beating may actively suppress tumor growth in cardiac tissues, a recent Science study reports. This is because cellular pathways in these tissues alter gene regulation in cancer cells to keep them from proliferating.
The findings shed light on the role of mechanical forces in protecting the heart from cancer and may pave the way to new cancer therapies based on mechanical stimulation.
Learn more on #WorldHeartDay: https://t.co/aqu8ZcPjaI
Presented at #ACC26:
Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: https://t.co/q0vNdAoJJL
Editorial: Paving the Road toward Targeted Lipid Lowering https://t.co/zUwmo0r0n4
@ACCinTouch
This is huge in the CV world ( $BMY / $CYTX / $EWTX); Mavacamten (BMS/MyoKardia) fails in Ph3 trial for non-obstructive HCM (ODYSSEY-HCM): https://t.co/GBoeJeGSiF
Bluebird Bio $BLUE sells itself to Carlyle, SK Capital for less than $30 million https://t.co/7CHuZxB5aK via @Jasonmmast
Its sale to private equity marks a quiet end for a biotech that, over the course of a dizzying decade, showcased both the power of modern genetic medicine to deliver cures for devastating rare diseases and the profound challenges any company would face in turning that power into a sustainable business.
🚨Capstan Therapeutics Preclinical Data on In Vivo CAR-T Candidate
-Robust in vivo engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in non-human primates
-Results obtained without the need for lymphodepletion chemotherapy
-Plans to advance CPTX2309 into the clinic in mid-2025 @capstantx #immunotherapy #Tcell #tcellrx #CARTCell https://t.co/LROHuya365
A faster, simpler, cheaper cancer cell therapy is about to be tested in humans
Australian regulators have authorized the first trial of in vivo CAR-T
https://t.co/5JBryewFSN
Stemming from our new data at #ASGCT2024, Tuyen Ong, CEO, was featured in a @FierceBiotech article spotlighting our Anellovector, a new class of viral vector, and it’s promise of redosability compared to traditional AAVs. Read about it here: https://t.co/rG7Moniavt
Today, @VerveTx is announcing updates to our PCSK9 program:
1. voluntarily pausing enrollment in the Heart-1 trail of VERVE-101
2. prioritizing clinical development of VERVE-102 which uses a different LNP delivery system
3. announcing clinical trial application have been cleared in U.K. & Canada for Heart-2 trial of VERVE-102
4. expect initiation of Heart-2 trial this quarter
Details:
1. 13 patients dosed so far in Heart-1 trial, 6 at 0.45 mg/kg dose
2. Efficacy: up to 73% reduction in LDL-C and durability out to 270 days after single treatment
3. However, at potentially therapeutic doses, seeing laboratory abnormalities
4. last patient dosed at 0.45 mg/kg experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia (a drop in the platelet count)
5. Lab changes transient, reversible, asymptomatic
6. Nevertheless, have elected to pause enrollment to investigate in order understand mechanism, if means to mitigate
7. Regulators informed; IND, CTAs for Heart-1 trial remain active
8. We believe lab safety findings attributable to lipid nanoparticle delivery system
9. For now, prioritizing development of VERVE-102
10. VERVE-102 uses an LNP with an ionizable lipid that has been tested in third-party clinical trials and well-tolerated
11. VERVE-102 also adds a GalNAc liver-targeting ligand
12. Expect to start Heart-2 trial of VERVE-102 in 2Q '24
Link to PR: https://t.co/GpkMT8eZIB
Today we announced that the Food & Drug Administration granted Fast Track Designation for EDG-5506 in Duchenne muscular dystrophy program. Check out our press release: https://t.co/rAhzSsTdjH
In Flagship’s 2024 Annual Letter, Founder & CEO
@NoubarAfeyan reflects on navigating the polycrisis and how to harness uncertainty and disequilibrium to propel progress and make the impossible possible. Read or listen to the letter here: https://t.co/AbVMp2Lrvw #WeAreFlagship #FlagshipJPM #JPM24
Second pig heart recipient dies, 6 wks after transplant (and 2 wks earlier than first). Sigh. https://t.co/hUZRvdpN1f Had recently shown signs of rejection.
1 could be flukey (or an odd viral infection). 2 could also be flukey, but does make me less hopeful, at least short term
A 27-year-old man with Duchenne’s muscular dystrophy who was treated with a CRISPR-Cas9 transgene died from an innate immune response to the high dose of recombinant AAV used for delivery of the transgene. Read the Brief Report: https://t.co/wPZuANiysn
interesting stuff there
Voyager Therapeutics $VYGR Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER-Generated Novel Capsids at the ASGCT 26th Annual Meeting https://t.co/CvEL6h5NPO